Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Zymeworks BC
ZW191 is an antibody-drug conjugate composed of a humanized IgG1 monoclonal antibody targeting folate receptor alpha conjugated to ZD06519, a camptothecin-based topoisomerase 1 inhibitor. Upon binding to FRα on tumor cells and cellular uptake, ZD06519 is released and inhibits DNA topoisomerase I, causing DNA strand breaks, cell cycle arrest, and apoptosis. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06555744 | Phase 1 | Advanced Solid Tumors | Active not recruiting | ZYME |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
Updated Oct 3, 2026. Something wrong or missing? Report it on the ZYME page.
See ZYME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZYME catalysts and pipeline →